Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results

 Intellia Therapeutics Inc. (NASDAQ:NTLA) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants.

Intellia saw its share prices soar by 23.20 percent to close at $14.92 apiece, as investors took heart from the encouraging results from Lonvo-Z, its treatment candidate for hereditary angioedema (HAE).

In a report over the weekend, Intellia Therapeutics Inc. (NASDAQ:NTLA) said that Lonvo-Z met its primary endpoint, with an 87 percent reduction in mean monthly attacks in the Lonvo-Z arm vs. the placebo group, from weeks 5 to 28.

For illustration purposes only. Photo by Gustavo Fring on Pexels

Of the enrolled patients, 62 percent in the Lonvo-Z arm were entirely attack-free and therapy-free for the six-month efficacy evaluation period, compared with 11 percent of patients in the placebo arm.

The treatment candidate also showed favorable safety and tolerability data.

“These are the first Phase 3 results to deliver on the much-heralded promise of in vivo CRISPR gene editing,” Intellia Therapeutics Inc. (NASDAQ:NTLA) President and CEO John Leonard said.

“Regardless of age or prior use of long-term prophylaxis therapies, it was observed that a single Lonvo-z treatment significantly reduced HAE attacks for all patients during the efficacy evaluation period, with all patients remaining LTP-free as of the data cutoff. We thank the many patients, physicians, and caregivers who participated in HAELO and are excited to be advancing this highly differentiated candidate toward a potential approval.”

Intellia Therapeutics Inc. (NASDAQ:NTLA) said that it remains on track to launch the treatment in the first half of 2027. A rolling biologics license application was submitted in April to the US Food and Drug Administration.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.